Progress of bridging therapy in CAR-T therapy for large B-cell lymphoma
10.12354/j.issn.1000-8179.2024.20240863
- VernacularTitle:桥接治疗在大B细胞淋巴瘤CAR-T治疗中的应用进展
- Author:
Yang JINGSHI
1
;
Fan JIAWEI
;
Hong HUANGMING
Author Information
1. 四川省肿瘤临床医学研究中心,四川省肿瘤医院·研究所,四川省癌症防治中心,电子科技大学附属肿瘤医院肿瘤内科(成都市 610041)
- Keywords:
bridging therapy;
B-cell lymphoma(BCL);
CAR-T cell therapy;
radiotherapy;
molecular targeted therapy
- From:
Chinese Journal of Clinical Oncology
2024;51(15):790-794
- CountryChina
- Language:Chinese
-
Abstract:
Bridging therapy serves as an adjunctive treatment during chimeric antigen receptor T cell therapy(CAR-T)and is specifically im-plemented after the collection of mononuclear cells but before the subsequent infusion of CAR-T cells.This approach can mitigate the pro-gression of large B-cell lymphoma(LBCL)to a certain extent,reduce tumor burden,and facilitate the infusion of CAR-T cells.Bridging therapy includes chemotherapy,radiation therapy,and targeted therapies and ensures effective reinfusion of CAR-T cells and enhances the thera-peutic efficacy of CAR-T cells.This study systematically reviews the significance,methodologies,and characteristics of CAR-T-cell-related bridging therapy for large B-cell lymphoma to provide valuable references for its clinical application.
